G1/23: Marketed Products Are Prior Art

The Enlarged Board of Appeal issued its decision in G1/23 on July 2, 2025, addressing whether products put on the market before a patent filing date form part of the prior art when their composition or internal structure cannot be reproduced by the skilled person.

G1/23: Marketed Products Are Prior Art

The Three Questions Referred

The referral arose from divergent case law on whether a product's non-reproducibility should exclude it from the state of the art. To resolve this inconsistency, the following questions were referred:

Question 1: Is a product put on the market before the date of filing of a European patent application to be excluded from the state of the art within the meaning of Article 54(2) EPC for the sole reason that its composition or internal structure could not be analysed and reproduced without undue burden by the skilled person before that date?

Question 2: If the answer to question 1 is no, is technical information about said product which was made available to the public before the filing date (e.g. by publication of technical brochure, non-patent or patent literature) state of the art within the meaning of Article 54(2) EPC, irrespective of whether the composition or internal structure of the product could be analysed and reproduced without undue burden by the skilled person before that date?

Question 3: If the answer to question 1 is yes or the answer to question 2 is no, which criteria are to be applied in order to determine whether or not the composition or internal structure of the product could be analysed and reproduced without undue burden within the meaning of opinion G 1/92? In particular, is it required that the composition and internal structure of the product be fully analysable and identically reproducible?

The Three Answers

Answer to Question 1: No. A product put on the market before the date of filing of a European patent application cannot be excluded from the state of the art within the meaning of Article 54(2) EPC for the sole reason that its composition or internal structure could not be analysed and reproduced by the skilled person before that date.

Answer to Question 2: Yes. Technical information about such a product which was made available to the public before the filing date forms part of the state of the art within the meaning of Article 54(2) EPC, irrespective of whether the skilled person could analyse and reproduce the product and its composition or internal structure before that date.

Answer to Question 3: In view of the answers to Questions 1 and 2, an answer is not required.

The Board examined what would happen if non-reproducible products were excluded from the prior art. They found this would lead to an absurd result: if products that cannot be reproduced were not prior art, then skilled persons could not rely on any starting materials, since all materials ultimately come from sources that cannot be reproduced from scratch. This chain of reasoning would empty the state of the art entirely.

What This Means

The Enlarged Board has effectively established what amounts to an on-sale bar at the EPO. Products put on the market are prior art, regardless of whether their composition is secret or whether they can be reverse-engineered. This means that any product sold or made publicly available before the priority date is prior art, along with all its analysable properties and any technical documentation about the product. 

G1/23 clarifies that public availability determines prior art status, not reproducibility. The decision removes the legal fiction that commercially available products do not form part of the state of the art, and aligns EPO practice with commercial reality by confirming that products available to skilled persons cannot be excluded from patentability assessments solely because their composition or manufacturing method cannot be reproduced.

AI for patents.

Be 50%+ more productive. Join thousands of legal professionals around the World using Solve’s Patent Copilot™ for drafting, prosecution, invention harvesting, and more.

Related articles

Why Patent Practice Needs Purpose-Built AI: Reflections from Code with Claude

Anthropic's Code with Claude convened the global community of developers, founders, and researchers building applied AI on Claude. Solve Intelligence was invited to speak from the stage on what we have learned building AI for patent professionals, and the conference was a useful reminder of why domain-specific software matters in high-stakes legal work.

Keunbong (KB) Do Joins Solve

We're delighted to welcome Keunbong (KB) Do to Solve Intelligence as our newest Legal and Product Engineer.

UPC Long-Arm Jurisdiction Is Reshaping European Patent Litigation

Three years in, the Unified Patent Court is no longer just a faster route through European patent litigation. It is becoming a single venue capable of resolving infringement across the UK, Switzerland, Turkey and Spain in one action. That shift has one source: the CJEU's BSH v Electrolux ruling, and what UPC divisions have done with it since February 2025.

The court has issued more than 1,800 decisions, with around 700 new actions a year and 31 already citing BSH. For teams navigating that volume across multiple jurisdictions, AI-assisted research platforms like Solve Intelligence exist for exactly this kind of work.

AI X IP Thought Leader Exchange with Solve Intelligence, Haynes Boone, and 100+ Leading Voices in IP

Solve Intelligence partnered with AmLaw 100 firm Haynes Boone to bring together 100+ senior IP leaders in Silicon Valley for a candid discussion on how AI is being used in patent practice today, and how that's shifting over the next 12 months.

The evening was led by Leah Poynter Waterland (Sr. Director, Cisco), Jeff Draeger (Chief Patent Counsel, Intel), David McCombs (Partner and Board Member, Haynes Boone), Tony Capecci (Director of Practice Innovation, Haynes Boone), and Mallun Yen (Founder, Operator Collective; IP leader and Ex-Cisco).

The room was 70% in-house, drawing Heads of IP and senior IP leaders from across enterprise software and cloud (Microsoft, IBM, Snowflake), semiconductors (Intel, Applied Materials), life sciences (Johnson & Johnson, Pfizer, Gilead), mobility and autonomy (Tesla, Waymo), connected devices and networks (Cisco, Samsung Research America), and AI labs (Mistral AI). The remaining 30% were outside counsel from firms including BCLP, Finnegan, Perkins Coie, Procopio, and Skadden.

Key Insights

  • Today, Solve supports global IP teams deploying AI agents for large-scale tasks including search across millions of patent and non-patent literature, portfolio analysis on thousands of assets, and claim charting, focussed on transparent source-backed and auditable outputs.
  • Every IP leader in the room had either rolled out an AI patent platform or was in active procurement.
  • Successful AI implementation requires collaboration and trusted long-term partnerships between IP teams, vendors, and outside counsel.
  • Solve CEO Chris Parsonson expects per-user token usage to grow more than 1000x over the next 12 months.